HRP20120424T1 - Derivati ureje, postupci za njihovu proizvodnju i njihova uporaba - Google Patents
Derivati ureje, postupci za njihovu proizvodnju i njihova uporaba Download PDFInfo
- Publication number
- HRP20120424T1 HRP20120424T1 HRP20120424TT HRP20120424T HRP20120424T1 HR P20120424 T1 HRP20120424 T1 HR P20120424T1 HR P20120424T T HRP20120424T T HR P20120424TT HR P20120424 T HRP20120424 T HR P20120424T HR P20120424 T1 HRP20120424 T1 HR P20120424T1
- Authority
- HR
- Croatia
- Prior art keywords
- groups
- group
- compound according
- ylethyl
- morpholin
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims 12
- 238000000034 method Methods 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 40
- 125000001424 substituent group Chemical group 0.000 claims abstract 33
- 125000000217 alkyl group Chemical group 0.000 claims abstract 32
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 12
- -1 trifluoromethoxyl Chemical group 0.000 claims abstract 12
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 10
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 9
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 9
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 9
- 229910052717 sulfur Chemical group 0.000 claims abstract 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract 8
- 125000005843 halogen group Chemical group 0.000 claims abstract 8
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 7
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract 7
- 125000003118 aryl group Chemical group 0.000 claims abstract 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 6
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims abstract 6
- 150000003462 sulfoxides Chemical class 0.000 claims abstract 6
- 239000011593 sulfur Chemical group 0.000 claims abstract 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 5
- 239000001301 oxygen Substances 0.000 claims abstract 5
- 150000003457 sulfones Chemical group 0.000 claims abstract 5
- 125000004001 thioalkyl group Chemical group 0.000 claims abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000003172 aldehyde group Chemical group 0.000 claims abstract 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract 3
- 125000000262 haloalkenyl group Chemical group 0.000 claims abstract 3
- 125000000232 haloalkynyl group Chemical group 0.000 claims abstract 3
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims abstract 3
- 125000005016 hydroxyalkynyl group Chemical group 0.000 claims abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- 125000006413 ring segment Chemical group 0.000 claims abstract 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 3
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 3
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims abstract 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims abstract 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 125000005842 heteroatom Chemical group 0.000 claims abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 125000003282 alkyl amino group Chemical group 0.000 claims 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 125000004442 acylamino group Chemical group 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 6
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 5
- 125000002757 morpholinyl group Chemical group 0.000 claims 5
- 229940124530 sulfonamide Drugs 0.000 claims 5
- 150000003456 sulfonamides Chemical class 0.000 claims 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 3
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 claims 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 3
- 239000004202 carbamide Substances 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 claims 2
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 229920001774 Perfluoroether Polymers 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 claims 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 2
- 125000005126 aryl alkyl carbonyl amino group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 2
- 125000004986 diarylamino group Chemical group 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 210000002990 parathyroid gland Anatomy 0.000 claims 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- OCOTWWSGPAHHQW-UHFFFAOYSA-N trifluoro(trifluoromethylsulfinyl)methane Chemical group FC(F)(F)S(=O)C(F)(F)F OCOTWWSGPAHHQW-UHFFFAOYSA-N 0.000 claims 2
- KAKQVSNHTBLJCH-UHFFFAOYSA-N trifluoromethanesulfonimidic acid Chemical compound NS(=O)(=O)C(F)(F)F KAKQVSNHTBLJCH-UHFFFAOYSA-N 0.000 claims 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 2
- GHQBXJDIFWSBHM-UHFFFAOYSA-N 1-(2-morpholin-4-ylethyl)-1-(3-phenyl-3-pyridin-4-ylpropyl)-3-(4-phenyl-1,3-thiazol-2-yl)urea Chemical compound C=1C=CC=CC=1C(C=1C=CN=CC=1)CCN(CCN1CCOCC1)C(=O)NC(SC=1)=NC=1C1=CC=CC=C1 GHQBXJDIFWSBHM-UHFFFAOYSA-N 0.000 claims 1
- NPNSOAQPRHIQCE-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)-3-(4-pyridin-2-yl-1,3-thiazol-2-yl)urea Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCN(CCN1CCOCC1)C(=O)NC(SC=1)=NC=1C1=CC=CC=N1 NPNSOAQPRHIQCE-UHFFFAOYSA-N 0.000 claims 1
- KGKGCIRNUKUTSM-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)-3-(4-pyridin-3-yl-2h-1,3-thiazol-3-yl)urea Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCN(CCN1CCOCC1)C(=O)NN1CSC=C1C1=CC=CN=C1 KGKGCIRNUKUTSM-UHFFFAOYSA-N 0.000 claims 1
- OKBTWRJXSAHHBA-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)-3-[4-(1,3-oxazol-2-yl)phenyl]urea Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCN(CCN1CCOCC1)C(=O)NC(C=C1)=CC=C1C1=NC=CO1 OKBTWRJXSAHHBA-UHFFFAOYSA-N 0.000 claims 1
- CSKYGKAVPJZAJT-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)-3-[4-(4-morpholin-4-ylphenyl)-1,3-thiazol-2-yl]urea Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCN(CCN1CCOCC1)C(=O)NC(SC=1)=NC=1C(C=C1)=CC=C1N1CCOCC1 CSKYGKAVPJZAJT-UHFFFAOYSA-N 0.000 claims 1
- IQIYMTRQCNWDRE-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)-3-[4-(4-pyrrolidin-1-ylphenyl)-1,3-thiazol-2-yl]urea Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCN(CCN1CCOCC1)C(=O)NC(SC=1)=NC=1C(C=C1)=CC=C1N1CCCC1 IQIYMTRQCNWDRE-UHFFFAOYSA-N 0.000 claims 1
- CIIJGMNXBMHIFX-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-3-(4-methoxy-1,3-benzothiazol-2-yl)-1-(2-morpholin-4-ylethyl)urea Chemical compound N=1C=2C(OC)=CC=CC=2SC=1NC(=O)N(CCN1CCOCC1)CCC(C=1C=CC=CC=1)C1=CC=CC=C1 CIIJGMNXBMHIFX-UHFFFAOYSA-N 0.000 claims 1
- NXNYLSJYKMJXBF-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-3-(4-phenyl-1,3-thiazol-2-yl)-1-(2-thiomorpholin-4-ylethyl)urea Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCN(CCN1CCSCC1)C(=O)NC(SC=1)=NC=1C1=CC=CC=C1 NXNYLSJYKMJXBF-UHFFFAOYSA-N 0.000 claims 1
- ZNTWXRLVCYUTBW-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-3-(5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)-1-(2-morpholin-4-ylethyl)urea Chemical compound S1C2=NC(OC)=CC=C2N=C1NC(=O)N(CCN1CCOCC1)CCC(C=1C=CC=CC=1)C1=CC=CC=C1 ZNTWXRLVCYUTBW-UHFFFAOYSA-N 0.000 claims 1
- SNQLYBYKPJDMFL-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-3-(6-methoxy-1,3-benzothiazol-2-yl)-1-(2-morpholin-4-ylethyl)urea Chemical compound S1C2=CC(OC)=CC=C2N=C1NC(=O)N(CCN1CCOCC1)CCC(C=1C=CC=CC=1)C1=CC=CC=C1 SNQLYBYKPJDMFL-UHFFFAOYSA-N 0.000 claims 1
- QJUFVKLGQSTXTR-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-3-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-1-(2-morpholin-4-ylethyl)urea;dihydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C1=CSC(NC(=O)N(CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN2CCOCC2)=N1 QJUFVKLGQSTXTR-UHFFFAOYSA-N 0.000 claims 1
- XEBXNYHWUYKCHS-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-3-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-1-(2-morpholin-4-ylethyl)urea Chemical compound C1=CC(OC)=CC=C1C1=CSC(NC(=O)N(CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN2CCOCC2)=N1 XEBXNYHWUYKCHS-UHFFFAOYSA-N 0.000 claims 1
- YIMABCZOADLIMV-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-3-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-1-(2-morpholin-4-ylethyl)urea Chemical compound C1=CC(C)=CC=C1C1=CSC(NC(=O)N(CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN2CCOCC2)=N1 YIMABCZOADLIMV-UHFFFAOYSA-N 0.000 claims 1
- ZYSCMWNXTDVXHM-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-3-[4-(4-methylsulfonylphenyl)-1,3-thiazol-2-yl]-1-(2-morpholin-4-ylethyl)urea Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CSC(NC(=O)N(CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN2CCOCC2)=N1 ZYSCMWNXTDVXHM-UHFFFAOYSA-N 0.000 claims 1
- PXARPBZBDSTBJI-UHFFFAOYSA-N 1-(3,3-dithiophen-2-ylpropyl)-1-(2-morpholin-4-ylethyl)-3-(4-phenyl-1,3-thiazol-2-yl)urea Chemical compound C=1C=CSC=1C(C=1SC=CC=1)CCN(CCN1CCOCC1)C(=O)NC(SC=1)=NC=1C1=CC=CC=C1 PXARPBZBDSTBJI-UHFFFAOYSA-N 0.000 claims 1
- DAOUFIPJJONZPB-UHFFFAOYSA-N 1-[2-(2,6-dimethylmorpholin-4-yl)ethyl]-1-(3,3-diphenylpropyl)-3-(4-phenyl-1,3-thiazol-2-yl)urea Chemical compound C1C(C)OC(C)CN1CCN(C(=O)NC=1SC=C(N=1)C=1C=CC=CC=1)CCC(C=1C=CC=CC=1)C1=CC=CC=C1 DAOUFIPJJONZPB-UHFFFAOYSA-N 0.000 claims 1
- HBFJWJHDSCJHDZ-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)-1-(2-morpholin-4-ylethyl)-1-(3-phenyl-3-pyridin-4-ylpropyl)urea Chemical compound N=1C2=CC=CC=C2SC=1NC(=O)N(CCN1CCOCC1)CCC(C=1C=CN=CC=1)C1=CC=CC=C1 HBFJWJHDSCJHDZ-UHFFFAOYSA-N 0.000 claims 1
- GCEKXNZJEPZBBC-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea Chemical compound N=1C2=CC=CC=C2SC=1NC(=O)N(CCN1CCOCC1)CCC(C=1C=CC=CC=1)C1=CC=CC=C1 GCEKXNZJEPZBBC-UHFFFAOYSA-N 0.000 claims 1
- XQBHEFGMHKTNSO-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)-1-(3,3-diphenylpropyl)-1-(2-thiomorpholin-4-ylethyl)urea Chemical compound N=1C2=CC=CC=C2SC=1NC(=O)N(CCN1CCSCC1)CCC(C=1C=CC=CC=1)C1=CC=CC=C1 XQBHEFGMHKTNSO-UHFFFAOYSA-N 0.000 claims 1
- USDXAKHZJQKEEJ-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)-1-(3,3-dithiophen-2-ylpropyl)-1-(2-morpholin-4-ylethyl)urea Chemical compound N=1C2=CC=CC=C2SC=1NC(=O)N(CCN1CCOCC1)CCC(C=1SC=CC=1)C1=CC=CS1 USDXAKHZJQKEEJ-UHFFFAOYSA-N 0.000 claims 1
- HWHZPANBXLRBMK-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)-1-[2-(2,6-dimethylmorpholin-4-yl)ethyl]-1-(3,3-diphenylpropyl)urea Chemical compound C1C(C)OC(C)CN1CCN(C(=O)NC=1SC2=CC=CC=C2N=1)CCC(C=1C=CC=CC=1)C1=CC=CC=C1 HWHZPANBXLRBMK-UHFFFAOYSA-N 0.000 claims 1
- SBRNTRWUMVKRJA-UHFFFAOYSA-N 3-(4-chloro-1,3-benzothiazol-2-yl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea Chemical compound N=1C=2C(Cl)=CC=CC=2SC=1NC(=O)N(CCN1CCOCC1)CCC(C=1C=CC=CC=1)C1=CC=CC=C1 SBRNTRWUMVKRJA-UHFFFAOYSA-N 0.000 claims 1
- RZJOMVBTCBDARA-UHFFFAOYSA-N 3-(6-chloro-1,3-benzothiazol-2-yl)-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea Chemical compound S1C2=CC(Cl)=CC=C2N=C1NC(=O)N(CCN1CCOCC1)CCC(C=1C=CC=CC=1)C1=CC=CC=C1 RZJOMVBTCBDARA-UHFFFAOYSA-N 0.000 claims 1
- BPMBGMPTGOHFED-UHFFFAOYSA-N 3-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea Chemical compound C1=CC(Cl)=CC=C1C1=CSC(NC(=O)N(CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN2CCOCC2)=N1 BPMBGMPTGOHFED-UHFFFAOYSA-N 0.000 claims 1
- BNHZLHHFLCFJEH-UHFFFAOYSA-N 3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(3,3-diphenylpropyl)-1-(2-morpholin-4-ylethyl)urea Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCN(CCN1CCOCC1)C(=O)NC(SC=1)=NC=1C1=CC=C(C#N)C=C1 BNHZLHHFLCFJEH-UHFFFAOYSA-N 0.000 claims 1
- MZTSRUJZTGWDGB-UHFFFAOYSA-N 5-[2-[[3,3-diphenylpropyl(2-morpholin-4-ylethyl)carbamoyl]amino]-1,3-thiazol-4-yl]-1,2-oxazole-3-carboxylic acid Chemical compound O1N=C(C(=O)O)C=C1C1=CSC(NC(=O)N(CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN2CCOCC2)=N1 MZTSRUJZTGWDGB-UHFFFAOYSA-N 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 208000015924 Lithiasis Diseases 0.000 claims 1
- 206010025476 Malabsorption Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 206010033964 Parathyroid tumour benign Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038478 Renal lithiasis Diseases 0.000 claims 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 1
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims 1
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims 1
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 claims 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 210000002449 bone cell Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 230000004094 calcium homeostasis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 210000003016 hypothalamus Anatomy 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 229910001410 inorganic ion Inorganic materials 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 230000008411 joint metabolism Effects 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- HNQIVZYLYMDVSB-NJFSPNSNSA-N methanesulfonamide Chemical compound [14CH3]S(N)(=O)=O HNQIVZYLYMDVSB-NJFSPNSNSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 201000003686 parathyroid adenoma Diseases 0.000 claims 1
- 208000014643 parathyroid gland adenoma Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 230000008560 physiological behavior Effects 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 210000003635 pituitary gland Anatomy 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Treating Waste Gases (AREA)
Abstract
Spoj formule (I): pri čemu: Y je kisik ili sumpor; R1 i R'1 su isti ili različiti, te svaki predstavlja arilnu skupinu, heteroarilnu skupinu, ili R1 i R'1, zajedno sa atomom ugljika na koji su vezani, formiraju kondenziranu prstenastu strukturu formule: gdje A predstavlja jednostruku vezu, metilnu skupinu, dimetilnu skupinu, kisik, dušik ili sumpor, navedeni sumpor je proizvoljno u sulfoksidnom ili sulfonskom obliku, pri čemu svaki R1 i R'1, ili navedena kondenzirana prstenasta struktura koja je tako formirana, proizvoljno su supstituirani sa najmanje jednim supstituentom odabranim iz skupine cpri čemu skupina c sadrži: atome halogena, hidroksil, karboksil, ravni i razgranati alkil, hidroksialkil, haloalkil, alkiltio, alkenil, te alkinilne skupine; ravne i razgranate alkoksil skupine; ravne i razgranate tioalkilne skupine; hidroksikarbonilalkil; alkilkarbonil; alkoksikarbonilalkil; alkoksikarbonil; trifluorometil; trifluorometoksil; -CN; -NO2; alkilsulfonilne skupine proizvoljno u sulfoksidnom ili sulfonskom obliku; pri čemu svaka alkilna komponenta ima od 1 do 6 atoma ugljika, i svaka alkenilna ili alkinilna komponenta ima od 2 do 6 atoma ugljika, te pri čemu, kada postoji više od jednog supstituenta, tada je svaki navedeni supstituent isti ili različit, R2 i R'2, koji mogu biti isti ili različiti, svaki predstavlja: atom vodika; ravnu ili razgranatu alkilnu skupinu koja sadrži od 1 do 6 atoma ugljika i proizvoljno je supstituirana sa barem jednim atomom halogena, hidroksi ili alkoksi skupinu koja sadrži od 1 do 6 atoma ugljika; alkilaminoalkil ili dialkilaminoalkil skupinu pri čemu svaka alkilna skupina sadrži od 1 do 6 atoma ugljika, ili R2 i R'2, zajedno sa atomom dušika na koji su spojeni, formiraju zasićeni ili nezasićeni heterocikal koji sadrži 0, 1 ili 2 dodatnih heteroatoma i koji ima 5, 6, ili 7 atoma u prstenu, navedeni heterocikal je proizvoljno supstituiran sa barem jednim supstituentom odabranim iz gore definirane skupine 'c', te pri čemu, kada postoji više od jednog supstituenta, navedeni supstituent je isti ili različit, R3 predstavlja skupinu formule: gdje B predstavlja atom kisika ili atom sumpora, x je 0, 1 ili 2, y i y' su isti ili različiti, i svaki je 0 ili 1, Ar i Ar' su isti ili različiti i svaki predstavlja aril ili heteroaril skupinu, n i n' su isti ili različiti, a svaki je 1, kada su y ili y' sa kojima je povezan jednaki 0, ili je jednak broju položaja koji mogu biti supstituirani na povezanom Ar ili Ar' kada navedeni y ili y' je 1, kondenzirani prsten koji sadrži Nx je petero- ili šestero-člani heteroarilni prsten, te pri čemu R i R', koji mogu biti isti ili različiti, svaki predstavlja atom vodika ili supstituent odabran iz skupine a, pri čemu skupina a sadrži: atome halogena; hidroksil; karboksil; aldehidne skupine; ravni i razgranati alkil, alkenil, alkinil, hidroksialkil, hidroksialkenil, hidroksialkinil, haloalkil, haloalkenil, te haloalkinilne skupine; ravne i razgranate alkoksilne skupine; ravne i razgranate ti
Claims (41)
1. Spoj formule (I):
[image]
pri čemu:
Y je kisik ili sumpor;
R1 i R'1 su isti ili različiti, te svaki predstavlja arilnu skupinu, heteroarilnu skupinu, ili R1 i R'1, zajedno sa atomom ugljika na koji su vezani, formiraju kondenziranu prstenastu strukturu formule:
[image]
gdje A predstavlja jednostruku vezu, metilnu skupinu, dimetilnu skupinu, kisik, dušik ili sumpor, navedeni sumpor je proizvoljno u sulfoksidnom ili sulfonskom obliku,
pri čemu svaki R1 i R'1, ili navedena kondenzirana prstenasta struktura koja je tako formirana, proizvoljno su supstituirani sa najmanje jednim supstituentom odabranim iz skupine c
pri čemu skupina c sadrži: atome halogena, hidroksil, karboksil, ravni i razgranati alkil, hidroksialkil, haloalkil, alkiltio, alkenil, te alkinilne skupine; ravne i razgranate alkoksil skupine; ravne i razgranate tioalkilne skupine; hidroksikarbonilalkil; alkilkarbonil; alkoksikarbonilalkil;
alkoksikarbonil; trifluorometil; trifluorometoksil; -CN; -NO2; alkilsulfonilne skupine proizvoljno u sulfoksidnom ili sulfonskom obliku; pri čemu svaka alkilna komponenta ima od 1 do 6 atoma ugljika, i svaka alkenilna ili alkinilna komponenta ima od 2 do 6 atoma ugljika,
te pri čemu, kada postoji više od jednog supstituenta, tada je svaki navedeni supstituent isti ili različit,
R2 i R'2, koji mogu biti isti ili različiti, svaki predstavlja: atom vodika; ravnu ili razgranatu alkilnu skupinu koja sadrži od 1 do 6 atoma ugljika i proizvoljno je supstituirana sa barem jednim atomom halogena, hidroksi ili alkoksi skupinu koja sadrži od 1 do 6 atoma ugljika; alkilaminoalkil ili dialkilaminoalkil skupinu pri čemu svaka alkilna skupina sadrži od 1 do 6 atoma ugljika,
ili R2 i R'2, zajedno sa atomom dušika na koji su spojeni, formiraju zasićeni ili nezasićeni heterocikal koji sadrži 0, 1 ili 2 dodatnih heteroatoma i koji ima 5, 6, ili 7 atoma u prstenu, navedeni heterocikal je proizvoljno supstituiran sa barem jednim supstituentom odabranim iz gore definirane skupine 'c',
te pri čemu, kada postoji više od jednog supstituenta, navedeni supstituent je isti ili različit,
R3 predstavlja skupinu formule:
[image]
gdje B predstavlja atom kisika ili atom sumpora, x je 0, 1 ili 2, y i y' su isti ili različiti, i svaki je 0 ili 1, Ar i Ar' su isti ili različiti i svaki predstavlja aril ili heteroaril skupinu, n i n' su isti ili različiti, a svaki je 1, kada su y ili y' sa kojima je povezan jednaki 0, ili je jednak broju položaja koji mogu biti supstituirani na povezanom Ar ili Ar' kada navedeni y ili y' je 1, kondenzirani prsten koji sadrži Nx je petero- ili šestero-člani heteroarilni prsten, te pri čemu R i R', koji mogu biti isti ili različiti, svaki predstavlja atom vodika ili supstituent odabran iz skupine a,
pri čemu skupina a sadrži: atome halogena; hidroksil; karboksil; aldehidne skupine; ravni i razgranati alkil, alkenil, alkinil, hidroksialkil, hidroksialkenil, hidroksialkinil, haloalkil, haloalkenil, te haloalkinilne skupine; ravne i razgranate alkoksilne skupine; ravne i razgranate tioalkilne skupine; aralkoksi skupine; ariloksi skupine; alkoksikarbonil; aralkoksikarbonil; ariloksikarbonil; hidroksikarbonilalkil; alkoksikarbonilalkil; aralkoksikarbonilalkil; ariloksikarbonilalkil; perfluoroalkil; perfluoroalkoksi; -CN; acil; amino, alkilamino, aralkilamino, arilamino, dialkilamino, diaralkilamino, diarilamino, acilamino, te diacilamino skupine; alkoksikarbonilamino, aralkoksikarbonilamino, ariloksikarbonilamino, alkilkarbonilamino, aralkilkarbonilamino, te arilkarbonilamino skupine; alkilaminokarboniloksi, aralkilaminokarboniloksi, i arilaminokarboniloksi skupine; alkilne skupine supstituirane sa amino, alkilamino, aralkilamino, arilamino, dialkilamino, diaralkilamino, diarilamino, acilamino, trifluorometilkarbonilamino, fluoroalkilkarbonilamino, ili diacilamino skupinom; CONH2; alkil-, aralkil-, te aril-amido skupine; alkiltio, ariltio i aralkiltio i njihove oksidirane sulfoksidne i sulfonske oblike; sulfonil, alkilsulfonil, haloalkilsulfonil, arilsulfonil i aralkilsulfonilne skupine; sulfonamid, alkilsulfonamid, haloalkilsulfonamid, di(alkilsulfonil)amino, aralkilsulfonamid, di(aralkilsulfonil)amino, arilsulfonamid, te di(arilsulfonil)amino; te zasićene i nezasićene heterociklilne skupine, navedene heterociklilne skupine su mono- ili bi-cikličke i proizvoljno su supstituirane sa jednim ili više supstituenata, koji mogu biti isti ili različiti, odabranih iz skupine b,
pri čemu skupina b sadrži: atome halogena; hidroksil; karboksil; aldehidne skupine; ravni i razgranati alkil, alkenil, alkinil, hidroksialkil, hidroksialkenil, hidroksialkinil, haloalkil, haloalkenil, i haloalkinilne skupine; ravne i razgranate alkoksilne skupine; ravne i razgranate tioalkilne skupine; alkoksikarbonil; hidroksikarbonilalkil; alkoksikarbonilalkil; perfluoroalkil; perfluoroalkoksi; -CN; acil; amino, alkilamino, dialkilamino, acilamino, te diacilamino skupine; alkilne skupine supstituirane sa amino, alkilamino, dialkilamino, acilamino, ili diacilamino skupinom; CONH2; alkilamido skupine; alkiltio i njihove oksidirane sulfoksidne i sulfonske oblike; sulfonil, alkilsulfonilne skupine; te sulfonamidne, alkilsulfonamidne, i di(alkilsulfonil)amino skupine
pri čemu, u skupinama a i b, bilo koja alkilna komponenta sadrži od 1 do 6 atoma ugljika, te bilo koje alkenilne ili alkinilne komponente koje sadrže od 2 do 6 atoma ugljika, te su proizvoljno supstituirane sa barem jednim atomom halogena ili hidroksi skupinom, a pri čemu bilo koja arilna komponenta je proizvoljno heteroarilna skupina,
te njihove soli i esteri.
2. Spoj prema zahtjevu 1, naznačen time da Y je kisik.
3. Spoj prema zahtjevu 1 ili 2, naznačen time da R1 i R'1 su isti ili različiti, i svaki predstavlja monocikličku arilnu skupinu, monocikličku heteroarilnu skupinu, ili R1 i R'1, zajedno sa atomom ugljika na koji su vezani, formiraju kondenziranu prstenastu strukturu formule:
[image]
gdje A je kako je definirano u zahtjevu 1,
pri čemu svaki R1 i R'1, ili navedena kondenzirana prstenasta struktura koja je tako formirana, je proizvoljno supstituirana sa barem jednim supstituentom odabranim iz skupine 'c' kako je definirano u zahtjevu 1.
4. Spoj prema zahtjevu 3, naznačen time da R1 i R'1 svaki predstavlja radikal fenila, piridinila, ili tienila, ili R1 i R'1 predstavljaju kondenziranu prstenastu strukturu kako je definirano u zahtjevu 1, pri čemu svaki R1 i R'1, ili navedena kondenzirana prstenasta struktura koja je tako formirana, je proizvoljno supstituirana kako je definirano u zahtjevu 1.
5. Spoj prema zahtjevu 3 ili 4, naznačen time da svaki R1 i R'1, ili navedena kondenzirana prstenasta struktura koja je tako formirana, proizvoljno je supstituirana sa barem jednim supstituentom odabranim iz skupine c': atomima fluora ili klora, hidroksilom, ravnim i razgranatim alkilom, alkiltio, hidroksialkilom, te fluoroalkilnim skupinama; ravnim i razgranatim alkoksil skupinama; trifluorometilom; trifluorometoksilom; -CN; alkilkarbonilnim skupinama; alkilsulfonilnim skupinama, te bilo koja alkilna komponenta ima od 1 do 4 atoma ugljika, te
pri čemu, kada postoji više od jednog supstituenta, tada je svaki navedeni supstituent isti ili različit.
6. Spoj prema zahtjevu 3 ili 4, naznačen time da svaki R1 i R'1, ili navedena kondenzirana prstenasta struktura koja je tako formirana, proizvoljno je supstituirana sa barem jednim supstituentom odabranim iz skupine koja sadrži: atome fluora ili klora, hidroksi skupine, ravne ili razgranate alkoksi skupine koje sadrže od 1 do 5 atoma ugljika, ravne ili razgranate alkilne skupine koje sadrže od 1 do 5 atoma ugljika, trifluorometil i trifluorometoksi skupine, i -CN skupine, te
pri čemu, kada postoji više od jednog supstituenta, tada je svaki navedeni supstituent isti ili različit.
7. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da svaki R1 i R'1 predstavljaju, proizvoljno supstituiranu, fenil, piridinil, ili tienil skupinu.
8. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da R2 i R'2, zajedno sa atomom dušika na koji su spojeni, formiraju zasićeni heterocikal koji sadrži 5, 6, ili 7 atoma u prstenu, navedeni heterocikal je proizvoljno supstituiran sa barem jednim supstituentom odabranim iz skupine 'c' koja je definirana u zahtjevu 1.
9. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time da R2 i R'2, koji mogu biti isti ili različiti, svaki predstavlja metil ili etilnu skupinu, ili, zajedno sa atomom dušika na koji su spojeni, formiraju morfolinil, tiomorfolinil, piperazinil, homopiperazinil, ili piperidinil skupinu, proizvoljno supstituiranu sa barem jednim supstituentom odabranim iz skupine koja sadrži: atome klora, hidroksilne skupine, trifluorometilne skupine, alkoksi skupine, hidroksialkilne skupine, te alkilne skupine.
10. Spoj prema zahtjevu 9, naznačen time da R2 i R'2, zajedno sa atomom dušika na koji su spojeni, formiraju morfolinilnu skupinu proizvoljno supstituiranu sa barem jednim supstituentom odabranim iz skupine koja sadrži: trifluorometilne skupine i alkilne skupine.
11. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da R2 i R'2, zajedno sa atomom dušika na koji su spojeni, formiraju morfolinilnu skupinu.
12. Spoj prema bilo kojem zahtjevu od 1 do 9, naznačen time da R2 i R'2, zajedno sa atomom dušika na koji su spojeni, formiraju tiomorfolinilnu skupinu.
13. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da R3 predstavlja skupinu formule:
[image]
pri čemu Ar, Ar', n, n', x, y, y', R, i R' su kako je definirano u zahtjevu 1.
14. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da R3 predstavlja tiazolilnu skupinu i barem jedan y je 0.
15. Spoj prema zahtjevu 14, naznačen time da jedan od Ary i Ar'y' je arilna ili heteroarilna skupina odabrana iz skupine koja sadrži: fenil, naftil, monocikličke heteroarile, i bicikličke heteroarile.
16. Spoj prema zahtjevu 15, naznačen time da jedan od Ary i Ar'y' je odabran iz skupine koja sadrži: fenil, naftil, tienil, tiazolil, izotiazolil, furanil, oksazolil, izoksazolil, imidazolil, triazolil, indolil, pirolil, piridinil, pirazinil, pirimidinil, te piridazinilne skupine.
17. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da su ne više od dva od svakih R i R' u skupinama AryRn i Ar'y'R'n', kada su jedan ili oba y i y' jednaki 1, odabrani od navedenih supstituenata a.
18. Spoj prema bilo kojem od zahtjeva od 1 do 13, naznačen time da R3 predstavlja skupinu formule:
[image]
pri čemu B, R i R' su kako je definirano u zahtjevu 1.
19. Spoj prema zahtjevu 18, naznačen time da B je atom sumpora.
20. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da svaki R i R' je odabran od vodika i supstituenata a': atoma fluora; atoma klora; hidroksilnih skupina; karboksilnih skupina; aldehidnih skupina; ravnog i razgranatog alkila, hidroksialkila, te fluoroalkilnih skupina; ravnih i razgranatih alkoksilnih skupina; ravnih i razgranatih tioalkilnih skupina; alkoksikarbonilnih skupina; benzilkarbonilnih skupina; hidroksikarbonilalkilnih skupina; alkoksikarbonilalkilnih skupina; trifluorometilnih skupina; trifluorometoksi skupina; -CN skupina; amino, alkilamino, dialkilamino, acilamino, te diacilamino skupina; alkoksikarbonilamino, alkilkarbonilamino skupina; alkilaminokarboniloksi skupina; alkilnih skupina supstituiranih sa amino, alkilamino, dialkilamino, acilamino, ili diacilamino skupinom; CONH2; alkilamido skupinama; alkiltio; alkilsulfoksid; sulfonilnim, te alkilsulfonilnim skupinama; sulfonamidnim, alkilsulfonamidnim, te di(alkilsulfonil)amino skupinama; trifluorometilsulfoksid; trifluorometilsulfonilnim skupinama; trifluorometilsulfonamidnim, te di(trifluorometilsulfonil)amino skupinama; alkilkarbonilalkil; i zasićenih monocikličkih heterociklilnih skupina, navedene heterociklilne skupine su proizvoljno supstituirane sa jednim ili više supstituenata, koji mogu biti isti ili različiti, odabrani iz skupine b kako je definirano u zahtjevu 1.
21. Spoj prema zahtjevu 20, naznačen time da svaki R i R' je odabran od vodika i supstituenata a": atoma klora; hidroksilnih skupina; karboksilnih skupina; ravnog i razgranatog alkila, hidroksialkila; ravnih i razgranatih alkoksilnih skupina; alkoksikarbonilnih skupina; hidroksikarbonilalkilnih skupina; alkoksikarbonilalkilnih skupina; trifluorometilnih skupina; trifluorometoksi skupina; -CN skupina; amino, alkilamino, i dialkilamino skupina; alkoksikarbonilamino, alkilkarbonilamino skupina; alkilaminokarboniloksi skupina; alkil skupina supstituiranih sa amino, alkilamino, ili dialkilamino skupinom; CONH2; alkilkarbonilalkil; alkiltio; sulfonilnim i alkilsulfonilnim skupinama; sulfonamidnim, alkilsulfonamidnim, i di(alkilsulfonil)amino skupinama; trifluorometilsulfoksidnim; trifluorometilsulfonilnim skupinama; trifluorometilsulfonamidnim, te di(trifluorometilsulfonil)amino skupinama; pirolidinil, piperidinil piperazinil, morfolinil, i tiomorfolinilnim skupinama proizvoljno supstituiranim sa jednim ili više supstituenata, koji mogu biti isti ili različiti, odabrani iz skupine b kako je definirano u zahtjevu 1.
22. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da supstituenti b su odabrani od supstituenata b' koji sadrže: atome klora; hidroksilne skupine; ravni i razgranati alkil, hidroksialkilne, te alkoksilne skupine; trifluorometilne skupine; trifluorometoksi skupine; -CN skupine; amino, alkilamino, te dialkilamino skupine; sulfonilne, alkilsulfonilne skupine; te sulfonamidne, alkilsulfonamidne, i di(alkilsulfonil)amino skupine.
23. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da svaki R i R' je odabran od vodika i skupina koji sadrže supstituente a" kako je definirano u zahtjevu 22, te pri čemu bilo koje pirolidinil, piperidinil piperazinil, morfolinil, te tiomorfolinilne skupine nisu dalje supstituirane.
24. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da bilo koja alkilna, alkenilna ili alkinilna komponenta nema više od 4 atoma ugljika.
25. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da bilo koji alkilsulfonilni supstituent je metilsulfonilni supstituent.
26. Spoj prema zahtjevu 1, naznačen time da je odabran od:
3-(6-klorobenzotiazol-2-il)-1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-ureje i njezinog dihidroklorida,
1-(3,3-difenilpropil)-3-(6-metoksibenzotiazol-2-il)-1-(2-morfolin-4-iletil)-ureje,
1-(3,3-difenilpropil)-3-(4-metoksibenzotiazol-2-il)-1-(2-morfolin-4-iletil)-ureje,
3-(4-klorobenzotiazol-2-il)-1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-ureje i njezinog dihidroklorida,
3-benzotiazol-2-il-1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-ureje i njezinog dihidroklorida,
1-(3,3-difenilpropil)-3-(5-metoksitiazolo[5,4-b]piridin-2-il)-1-(2-morfolin-4-iletil)-ureje,
1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-3-(4-oksazol-2-ilfenil)ureje i njezinog dihidroklorida,
3-[4-(4-klorofenil)tiazol-2-il]-1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-ureje i njezinog dihidroklorida,
1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-3-(4-p-toliltiazol-2-il)ureje i njezinog dihidroklorida,
etil estera 5-{2-[3-(3,3-difenilpropil)-3-(2-morfolin-4-iletil)ureido]tiazol-4-il}-izoksazol-3-karboksilne kiseline i njezinog dihidroklorida,
1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-3-[4-(4-pirolidin-1-ilfenil)-tiazol-2-il]ureje i njezinog trihidroklorida,
1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-3-[4-(4-morfolin-4-ilfenil)-tiazol-2-il]ureje,
3-[4-(4-cijanofenil)tiazol-2-il]-1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-ureje i njezinog dihidroklorida,
1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-3-(4-piridin-2-iltiazol-2-il)ureje,
1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-3-(4-piridin-3-iltiazol-3-il)ureje i njezinog trihidroklorida,
1-(3,3-difenilpropil)-1-(2-morfolin-4-iletil)-3-[4-(2-oxo-2,3-dihydro-benzoksazol-6-il)tiazol-2-il]ureje,
1-(3,3-difenilpropil)-3-[4-(4-(fluorofenil)-5-metiltiazol-2-il]-1-(2-morfolin-4-iletil)ureje i njezinog hidroklorida,
1-(3,3-difenilpropil)-3-[4-(4-(fluorofenil)tiazol-2-il]-1-(2-morfolin-4-iletil)ureje,
1-(3,3-difenilpropil)-3-[4-(5-metilfuran-2-il)tiazol)-2-il]-1-(2-morfolin-4-iletil)ureje i njezinog dihidroklorida,
N-(4-{2-[3-(3,3-difenilpropil)-3-(2-morfolin-4-iletil)ureido]tiazol-4-il-fenil)]metanesulfonamida i njegovog dihidroklorida,
3-benzotiazol-2-il-1-(2-morfolin-4-iletil)-1-(3-fenil-3-piridin-4-ilpropil)-ureje,
1-(2-morfolin-4-iletil)-1-(3-fenil-3-piridin-4-ilpropil)-3-(4-feniltiazol-2-il)ureje,
N-(4-{2-[3-(3,3-difenilpropil)-3-(2-morfolin-4-iletil)ureido]-[4-tiazol-4-il}fenil)-acetamida,
1-(3,3-difenilpropil)-3-[4-(4-metoksifenil)tiazol-2-il]-1-(2-morfolin-4-iletil)ureje i njezinog dihidroklorida,
1-(3,3-difenilpropil)-3-[4-(4-metanesulfonilfenil)tiazol-2-il]-1-(2-morfolin-4-il-etil)ureje i njezinog dihidroklorida
1-(3,3-difenilpropil)-3-[4-(4-fluorofenil)tiazol-2-il]-1-(2-morfolin-4-iletil)ureje i njezinog dihidroklorida,
3-benzotiazol-2-il-1-(3,3-difenilpropil)-1-(2-tiomorfolin-4-iletil)ureje,
1-(3,3-difenilpropil)-3-(4-feniltiazol-2-il)-1-(2-tiomorfolin-4-iletil)ureje,
3-benzotiazol-2-il-1-[2-(2,6-dimetilmorfolin-4-il)etil]-1-(3,3-difenilpropil)ureje,
1-[2-(2,6-dimetilmorfolin-4-il)etil]-1-(3,3-difenilpropil)-3-(4-feniltiazol-2-il)-ureje,
1-(3,3-ditiofen-2-ilpropil)-1-(2-morfolin-4-iletil)-3-(4-feniltiazol-2-il)ureje, te
3-benzotiazol-2-il-1-(3,3-ditiofen-2-ilpropil)-1-(2-morfolin-4-iletil)ureje.
27. Uporaba spoja prema bilo kojem prethodnom zahtjevu naznačena time da je za liječenje.
28. Farmaceutski prihvatljiv pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1 do 26.
29. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačen time da je za proizvodnju lijeka za liječenje ili sprečavanje bolesti ili poremećaja povezanih sa nenormalnim fiziološkim ponašanjem anorganskih ionskih receptora i naročito receptora kalcija.
30. Uporaba prema zahtjevu 29, naznačena time da je receptor kalcija izražen u paratiroidnoj žlijezdi, štitnjači, koštanim stanicama, stanicama bubrega, plućima, mozgu, hipofizi, hipotalamusu, gastrointestinalnima stanicama, stanicama gušterače, stanicama kože, stanicama središnjeg ili perifernog živčanog sustava i glatkim mišićnim stanicama.
31. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačena time da je za proizvodnju lijeka za sprečavanje ili liječenje raka, naročito paratireoidne žlijezde i probavnog trakta.
32. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačena time da je za proizvodnju lijeka za sprečavanje ili liječenje neurodegenerativnih bolesti.
33. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačena time da je za proizvodnju lijeka za sprečavanje ili liječenje bolesti kostiju i metabolizma zglobova, naročito osteoporoze, osteopenije i Pagetove bolesti, reumatoidnog artritisa i osteoartritisa.
34. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačena time da je za proizvodnju lijeka za sprečavanje ili liječenje nenormalne homeostaze kalcija.
35. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačena time da je za proizvodnju lijeka za sprečavanje ili liječenje hiperplazije i paratiroidnog adenoma.
36. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačena time da je za proizvodnju lijeka za sprečavanje ili liječenje intestinalne malapsorpcije.
37. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačena time da je za proizvodnju lijeka za sprečavanje ili liječenje žučne litijaze i bubrežne litijaze.
38. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačena time da je za proizvodnju lijeka za sprečavanje ili liječenje hiperparatiroidizma.
39. Uporaba prema zahtjevu 38, naznačena time da je sekundarni hiperparatiroidizam uočen u slučaju zatajenja bubrega.
40. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačena time da je za proizvodnju lijeka za sprečavanje ili liječenje smanjenja razine ioniziranog kalcija u serumu tijekom liječenja hiperkalcemije.
41. Uporaba spoja prema bilo kojem od zahtjeva 1 do 26 naznačena time da je za proizvodnju lijeka za sprečavanje ili liječenje kardiovaskularnih bolesti i posebice povišenog krvnog tlaka.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0504360A FR2885129B1 (fr) | 2005-04-29 | 2005-04-29 | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
PCT/EP2006/004166 WO2006117211A2 (en) | 2005-04-29 | 2006-04-24 | Urea derivatives methods for their manufacture and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120424T1 true HRP20120424T1 (hr) | 2012-06-30 |
Family
ID=35311522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120424TT HRP20120424T1 (hr) | 2005-04-29 | 2012-05-17 | Derivati ureje, postupci za njihovu proizvodnju i njihova uporaba |
Country Status (25)
Country | Link |
---|---|
US (2) | US8247412B2 (hr) |
EP (2) | EP1874765B1 (hr) |
JP (1) | JP4995189B2 (hr) |
KR (1) | KR20080003380A (hr) |
CN (1) | CN101238120A (hr) |
AR (1) | AR056991A1 (hr) |
AT (1) | ATE548368T1 (hr) |
AU (1) | AU2006243328B2 (hr) |
BR (1) | BRPI0611025A2 (hr) |
CA (1) | CA2605008A1 (hr) |
CR (1) | CR9469A (hr) |
CY (1) | CY1112960T1 (hr) |
DK (1) | DK1874765T3 (hr) |
EA (1) | EA200702375A1 (hr) |
ES (1) | ES2384052T3 (hr) |
FR (1) | FR2885129B1 (hr) |
HR (1) | HRP20120424T1 (hr) |
IL (1) | IL186854A0 (hr) |
NO (1) | NO20076145L (hr) |
PL (1) | PL1874765T3 (hr) |
PT (1) | PT1874765E (hr) |
TW (1) | TW200714598A (hr) |
UY (1) | UY29510A1 (hr) |
WO (1) | WO2006117211A2 (hr) |
ZA (1) | ZA200708871B (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2885129B1 (fr) | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
DE602006010905D1 (de) | 2005-11-25 | 2010-01-14 | Galapagos Sas | Harnstoff-derivate als calcium-rezeptor-modulatoren |
CN101437490A (zh) | 2006-04-20 | 2009-05-20 | 安美基公司 | 稳定乳液配方 |
GB0613674D0 (en) * | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
AU2008233088B2 (en) | 2007-03-30 | 2013-09-26 | Amgen Inc. | Calcimimetic compounds for use in the treatment of bowel disorders |
EP2156846B1 (en) * | 2007-05-08 | 2014-08-13 | Ajinomoto Co., Inc. | Prophylactic or therapeutic agent for diarrhea |
EP2176247A2 (en) * | 2007-07-10 | 2010-04-21 | Amgen Inc. | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
WO2010104882A1 (en) | 2009-03-10 | 2010-09-16 | Amgen Inc. | Methods of modulating sperm motility |
US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
JP6522602B2 (ja) | 2013-07-02 | 2019-05-29 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Rock阻害剤としての三環式ピリド−カルボキサミド誘導体 |
EP3016951B1 (en) | 2013-07-02 | 2017-05-31 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
RS62915B1 (sr) * | 2015-03-03 | 2022-03-31 | Biohaven Therapeutics Ltd | Prolekovi riluzola i njihova primena |
CN106946851B (zh) * | 2017-03-14 | 2019-11-12 | 牡丹江医学院 | 一种用于预防和治疗肾结石的药物 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3897242A (en) | 1968-02-13 | 1975-07-29 | Ciba Geigy Ag | Use of 1-(3-chloro-4-methylphenyl)-3,3-dimethylurea in wheat and barley crops |
IL31574A0 (en) | 1968-02-13 | 1969-04-30 | Ciba Ltd | Use of certain ureas for combating weeds |
JPS58109464A (ja) | 1981-12-23 | 1983-06-29 | Nippon Paint Co Ltd | アミノ酸化合物、その製法ならびに触媒 |
US4579947A (en) | 1983-06-16 | 1986-04-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder |
US4521583A (en) | 1984-02-09 | 1985-06-04 | American Cyanamid Company | Curable epoxy resin compositions |
US4594373A (en) | 1984-02-09 | 1986-06-10 | American Cyanamid Company | Curable epoxy resin compositions |
FR2601363B1 (fr) * | 1986-07-08 | 1988-10-21 | Synthelabo | (dimethylamino)-2 ethyl) ((((methylthio)-2 phenyl) (phenylmethyl)amino)-2 oxo-2 ethyl) carbamates ou urees, leur preparation et leur application en therapeutique. |
US5242947A (en) | 1988-02-10 | 1993-09-07 | New York University | Use of polyamines as ionic-channel regulating agents |
US5227397A (en) | 1989-04-28 | 1993-07-13 | Pfizer Inc. | Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels |
DD298412A5 (de) | 1989-04-28 | 1992-02-20 | ������@���Kk�� | Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele |
EP0597830A1 (en) | 1989-07-03 | 1994-05-25 | New York University Nyu Medical Center | Use of polyamines as ionic-channel regulating agents |
US5153226A (en) | 1989-08-31 | 1992-10-06 | Warner-Lambert Company | Acat inhibitors for treating hypocholesterolemia |
CA2096528C (en) | 1990-11-19 | 2005-12-06 | Kathryn Lea Reed | Retroviral protease inhibitors |
US5312928A (en) | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
CA2173747C (en) | 1991-08-23 | 2006-05-23 | Edward F. Nemeth | Calcium receptor-active arylalkyl amines |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
KR100290516B1 (ko) | 1992-05-20 | 2001-09-17 | 죤 에이치. 뷰센 | 레트로바이러스프로테아제억제인자의합성에유용한중간생성물의제조방법 |
DK1302468T3 (da) | 1992-12-29 | 2009-03-02 | Abbott Lab | Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease |
JPH0841006A (ja) | 1994-08-05 | 1996-02-13 | Nisshin Flour Milling Co Ltd | ジウレア誘導体 |
DE69533948T2 (de) | 1994-10-21 | 2005-12-15 | NPS Pharmaceuticals, Inc., Salt Lake City | Kalzium-Rezeptor aktive Verbindungen |
CN1055681C (zh) | 1994-11-04 | 2000-08-23 | 参天制药株式会社 | 带有羟基的新1,3-二烷基脲衍生物 |
EP0798291B1 (en) | 1994-12-14 | 2002-09-11 | Santen Pharmaceutical Co., Ltd. | Novel 1,3-dialkylurea derivatives |
JP3306571B2 (ja) | 1995-06-28 | 2002-07-24 | 参天製薬株式会社 | エンドセリン変換酵素阻害剤 |
JPH10195037A (ja) | 1996-02-15 | 1998-07-28 | Tanabe Seiyaku Co Ltd | フェノール誘導体 |
CA2197364A1 (en) | 1996-02-15 | 1997-08-16 | Toshikazu Suzuki | Phenol compound and process for preparing the same |
CA2251331C (en) | 1996-04-09 | 2009-06-09 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
EP1019367A1 (en) | 1997-08-05 | 2000-07-19 | Novo Nordisk A/S | Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use |
JPH11139969A (ja) | 1997-08-07 | 1999-05-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
WO1999037604A2 (en) | 1998-01-21 | 1999-07-29 | Zymogenetics, Inc. | Dialkyl ureas as calcitonin mimetics |
DK1169038T3 (da) | 1999-04-15 | 2012-11-26 | Bristol Myers Squibb Co | Cykliske proteintyrosinkinaseinhibitorer |
US6365617B1 (en) * | 1999-06-29 | 2002-04-02 | Ortho-Mcneil Pharmaceutical, Inc. | Indole and indazole urea-peptoids as thrombin receptor antagonists |
FR2809396B1 (fr) | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
FR2820136A1 (fr) | 2001-01-26 | 2002-08-02 | Aventis Pharma Sa | Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
US6598746B2 (en) * | 2001-09-13 | 2003-07-29 | Washburn Graphics, Inc. | Display carton having an internally reinforced hanger panel |
AU2003272767A1 (en) | 2002-09-30 | 2004-04-23 | Schering Corporation | Use of tricyclic amides for the treatment of disorders of calcium homeostasis |
JP2005336173A (ja) * | 2004-04-27 | 2005-12-08 | Santen Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
US8362274B2 (en) | 2004-05-28 | 2013-01-29 | Mitsubishi Tanabe Pharma Corporation | Arylalkylamine compound and process for preparing the same |
FR2885129B1 (fr) | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
WO2006123725A1 (ja) | 2005-05-19 | 2006-11-23 | Astellas Pharma Inc. | ピロリジン誘導体またはその塩 |
DE602006010905D1 (de) | 2005-11-25 | 2010-01-14 | Galapagos Sas | Harnstoff-derivate als calcium-rezeptor-modulatoren |
GB0613674D0 (en) | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
EP2176247A2 (en) | 2007-07-10 | 2010-04-21 | Amgen Inc. | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
-
2005
- 2005-04-29 FR FR0504360A patent/FR2885129B1/fr not_active Expired - Fee Related
-
2006
- 2006-04-24 KR KR1020077024941A patent/KR20080003380A/ko not_active Application Discontinuation
- 2006-04-24 EP EP06724709A patent/EP1874765B1/en active Active
- 2006-04-24 EP EP11002964A patent/EP2354137A1/en not_active Withdrawn
- 2006-04-24 BR BRPI0611025A patent/BRPI0611025A2/pt not_active IP Right Cessation
- 2006-04-24 DK DK06724709.8T patent/DK1874765T3/da active
- 2006-04-24 AU AU2006243328A patent/AU2006243328B2/en not_active Ceased
- 2006-04-24 JP JP2008508167A patent/JP4995189B2/ja not_active Expired - Fee Related
- 2006-04-24 AT AT06724709T patent/ATE548368T1/de active
- 2006-04-24 CA CA002605008A patent/CA2605008A1/en not_active Abandoned
- 2006-04-24 CN CNA2006800145076A patent/CN101238120A/zh active Pending
- 2006-04-24 PT PT06724709T patent/PT1874765E/pt unknown
- 2006-04-24 PL PL06724709T patent/PL1874765T3/pl unknown
- 2006-04-24 WO PCT/EP2006/004166 patent/WO2006117211A2/en active Application Filing
- 2006-04-24 EA EA200702375A patent/EA200702375A1/ru unknown
- 2006-04-24 US US11/919,537 patent/US8247412B2/en not_active Expired - Fee Related
- 2006-04-24 ES ES06724709T patent/ES2384052T3/es active Active
- 2006-04-26 AR ARP060101666A patent/AR056991A1/es unknown
- 2006-04-26 TW TW095114960A patent/TW200714598A/zh unknown
- 2006-04-28 UY UY29510A patent/UY29510A1/es not_active Application Discontinuation
-
2007
- 2007-10-16 ZA ZA200708871A patent/ZA200708871B/xx unknown
- 2007-10-23 IL IL186854A patent/IL186854A0/en unknown
- 2007-10-23 CR CR9469A patent/CR9469A/es unknown
- 2007-11-28 NO NO20076145A patent/NO20076145L/no not_active Application Discontinuation
-
2012
- 2012-05-17 HR HRP20120424TT patent/HRP20120424T1/hr unknown
- 2012-06-06 CY CY20121100508T patent/CY1112960T1/el unknown
- 2012-06-27 US US13/535,198 patent/US20120283255A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2605008A1 (en) | 2006-11-09 |
US20100240889A1 (en) | 2010-09-23 |
IL186854A0 (en) | 2008-02-09 |
JP4995189B2 (ja) | 2012-08-08 |
EA200702375A1 (ru) | 2008-06-30 |
CN101238120A (zh) | 2008-08-06 |
NO20076145L (no) | 2008-01-28 |
CY1112960T1 (el) | 2016-04-13 |
US20120283255A1 (en) | 2012-11-08 |
AR056991A1 (es) | 2007-11-07 |
ZA200708871B (en) | 2009-03-25 |
BRPI0611025A2 (pt) | 2016-11-16 |
DK1874765T3 (da) | 2012-06-18 |
ATE548368T1 (de) | 2012-03-15 |
JP2008539186A (ja) | 2008-11-13 |
FR2885129B1 (fr) | 2007-06-15 |
EP1874765A2 (en) | 2008-01-09 |
EP2354137A1 (en) | 2011-08-10 |
CR9469A (es) | 2008-03-06 |
WO2006117211A3 (en) | 2007-01-11 |
PL1874765T3 (pl) | 2012-08-31 |
FR2885129A1 (fr) | 2006-11-03 |
AU2006243328A1 (en) | 2006-11-09 |
TW200714598A (en) | 2007-04-16 |
WO2006117211A2 (en) | 2006-11-09 |
AU2006243328B2 (en) | 2011-09-08 |
US8247412B2 (en) | 2012-08-21 |
PT1874765E (pt) | 2012-05-25 |
KR20080003380A (ko) | 2008-01-07 |
UY29510A1 (es) | 2006-12-29 |
EP1874765B1 (en) | 2012-03-07 |
ES2384052T3 (es) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120424T1 (hr) | Derivati ureje, postupci za njihovu proizvodnju i njihova uporaba | |
AU2013251632B2 (en) | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation | |
CN103502237B (zh) | Faah抑制剂 | |
JP4636486B2 (ja) | 脈管形成阻害活性を有するアリール尿素 | |
WO2020014246A1 (en) | Pyridine carboxamide compounds for inhibiting nav1.8 | |
AU2015355839B2 (en) | Heterocyclic derivatives and use thereof | |
JP2010519181A5 (hr) | ||
RU2006134004A (ru) | Производные гетероариламинопиразола, пригодные для лечения диабета | |
ZA200206077B (en) | Adenosine receptor modulators. | |
NO169286C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolin-2-okso-1-karboksylsyrederivater | |
HRP20140611T1 (hr) | Inhibitori kinaze p70 s6 | |
HUE025520T2 (en) | BACE inhibitor aminohydrothiazine derivatives for the treatment of Alzheimer's disease | |
NO20064166L (no) | Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter | |
AU2011272800A1 (en) | sGC stimulators | |
AU2006278829A1 (en) | GSK-3 inhibitors | |
RU2006138433A (ru) | Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2 | |
AR061793A1 (es) | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica | |
CA2982267C (en) | Novel dgat2 inhibitors | |
EP3233847A1 (en) | Amido thiadiazole derivatives as nadph oxidase inhibitors | |
CN105968090A (zh) | 甲酰胺化合物和它们作为需钙蛋白酶抑制剂的用途 | |
JP2006510728A5 (hr) | ||
RU2009123841A (ru) | Замещенные производные 2,5-дигидро-3н-пиразоло[4,3-c]пиридазин-3-она, их получение и их применение в терапии | |
HRP20120069T1 (hr) | Derivati 5,6-bisaril-2-piridinkarboksamida, njihovo dobivanje i njihova upotreba u terapiji kao antagonista receptora urotenzina ii | |
CA2729649A1 (en) | Thiazopyrimidinones and uses thereof | |
JP2022123114A (ja) | スルフィニルアミノベンズアミドおよびスルホニルアミノベンズアミド誘導体 |